Vitiligo - An autoimmune side-effect of intravesical bacillus Calmette-Guérin instillation?

Scandinavian Journal of Urology and Nephrology

Volumn 38, Issue 2, 2004, Pages 182-183

  Beisland, Christian ^a   Holsen, Dag Sollesnes ^a  

^a HAUKELAND UNIVERSITY HOSPITAL   (Norway)

Author keywords

Autoimmune reaction; Bacillus Calmette Gu rin treatment; Bladder; Immunostimulation; Transitional cell carcinoma; Vitiligo

Indexed keywords

BCG VACCINE;

ADULT; ARTICLE; AUTOIMMUNE DISEASE; BIOPSY; BLADDER CARCINOMA; BLOOD EXAMINATION; CANCER DIAGNOSIS; CANCER STAGING; CASE REPORT; CLINICAL FEATURE; CYSTECTOMY; DRUG INSTILLATION; HUMAN; MALE; PIGMENTED NEVUS; PRIORITY JOURNAL; SKIN BIOPSY; SUPERFICIAL CANCER; SYMPTOM; TRANSITIONAL CELL CARCINOMA; VITILIGO;

ADMINISTRATION, INTRAVESICAL; AUTOANTIBODIES; BCG VACCINE; CARCINOMA, TRANSITIONAL CELL; HUMANS; MALE; MIDDLE AGED; URINARY BLADDER NEOPLASMS; VITILIGO;

EID: 1942453836     PISSN: 00365599     EISSN: None     Source Type: Journal    
DOI: 10.1080/00365590310021357     Document Type: Article

References (6)

1. Njoo MD, Westerhof W. Vitiligo. Pathogenesis and treatment. Am J Clin Dermatol 2001; 2: 167-81.
2. Kemp EH, Waterman EA, Weetman AP. Autoimmune aspects of vitiligo. Autoimmunity 2001; 34: 65-77.
3. Phan GQ, Attia P, Steinberg SM, White DE, Rosenberg SA. Factors associated with response to high-dose interleukin-2 in patients with metastatic melanoma. J Clin Oncol 2001; 19: 3477-82.
4. Raanani P, Ben-Bassat I. Immune-mediated complications during interferon therapy in hematological patients. Acta Haematol 2002; 107: 133-44.
5. Cohen Y, Haim S, Bartal A, Robinson E. Vitiligo associated with BCG-methanol extraction residue in malignant melanoma. Report of a case. Dermatologica 1979; 158: 8-12.
6. Lamm DL. How long should adjuvant BCG be given? In: Kurth KH, Mickisch GH, Schroeder FH, eds. Renal, bladder and prostate cancer: an update. London: Parthenon Publishing Group, 1999: 235-44.